Breakthrough in targeted therapy for non-small cell lung cancer - 19/12/20
pages | 10 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Targeted therapy has improved the survival rate and extended the survival time of patients. |
• | Targeted therapy has greater advantages than chemotherapy with low side effects. |
• | Discussing and comparing the advantages and disadvantages of multiple targeted inhibitors. |
Abstract |
Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of lung cancer which causes more and more mortality in recent years. NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In recent years, cellular and molecular biotechnology has developed rapidly, and researchers have begun to target key genes and regulatory molecules for treatment. Targeted drugs have also emerged. The purpose of this review is to introduce important research achievements in recent years and the treatment progress of new drugs.
Le texte complet de cet article est disponible en PDF.Abbreviations : ALK, BBB, BIRC, DCR, EGFR, FISH, HR, mPFS, NSCLC, NCCN, ORR, OS, PFS, TKI
Keywords : Non-small cell lung cancer, Targeted therapy, Chemotherapy, EGFR, ALK
Plan
Vol 133
Article 111079- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?